Publikationen von Johannes M. Heuckmann
Alle Typen
Zeitschriftenartikel (14)
2015
Zeitschriftenartikel
16, 7 (2015)
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biology
Zeitschriftenartikel
526 (7575), S. 700 - 704 (2015)
Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature
Zeitschriftenartikel
6 (36), S. 38458 - 38468 (2015)
Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget 2014
Zeitschriftenartikel
4 (4), S. 415 - 422 (2014)
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discovery
Zeitschriftenartikel
4 (2), S. 246 - 257 (2014)
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discovery 2012
Zeitschriftenartikel
18 (17), S. 4682 - 4690 (2012)
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clinical Cancer Research
Zeitschriftenartikel
44 (10), S. 1104- - 11xx (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics
Zeitschriftenartikel
109 (42), S. 17034 - 17039 (2012)
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America 2011
Zeitschriftenartikel
1 (1), S. 78 - 89 (2011)
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery
Zeitschriftenartikel
17 (23), S. 7394 - 7401 (2011)
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research
Zeitschriftenartikel
71 (14), S. 4920 - 4931 (2011)
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Research 2010
Zeitschriftenartikel
70 (3), S. 868 - 874 (2010)
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Research
Zeitschriftenartikel
2 (62), S. 62ra93 - 62ra93 (2010)
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine 2009
Zeitschriftenartikel
106, S. 18351 - 18356 (2009)
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America